- Home
- CHRS vs FENC Comparison
CHRS vs FENC Comparison
Compare CHRS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRS | FENC |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.7M | 384.0M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CHRS | FENC |
|---|---|---|
| Price | $1.16 | $10.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $7.75 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 1.1M | 160.4K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $44.19 | $62.55 |
| Revenue Next Year | $65.06 | $42.10 |
| P/E Ratio | ★ N/A | $178.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $5.65 |
| 52 Week High | $2.62 | $13.25 |
Technical Indicators
Market Signals| Indicator | CHRS | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 43.64 |
| Support Level | N/A | $10.09 |
| Resistance Level | $1.53 | $11.29 |
| Average True Range (ATR) | 0.09 | 0.43 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 30.30 | 46.77 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.